BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 33649101)

  • 21. A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.
    Guettinger Y; Barbin K; Peipp M; Bruenke J; Dechant M; Horner H; Thierschmidt D; Valerius T; Repp R; Fey GH; Stockmeyer B
    J Immunol; 2010 Feb; 184(3):1210-7. PubMed ID: 20042573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential binding to frequent HLA-A alleles of p21 RAS derived peptides bearing oncogenic substitutions at position 12 or 13.
    Gouttefangeas C; Demeur C; Connan F; Balayn N; Choppin J; Tilkin-Mariamé AF
    Hum Immunol; 1997 Jul; 55(2):117-26. PubMed ID: 9361963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.
    Abrams SI; Stanziale SF; Lunin SD; Zaremba S; Schlom J
    Eur J Immunol; 1996 Feb; 26(2):435-43. PubMed ID: 8617315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release.
    Aschmoneit N; Kühl L; Seifert O; Kontermann RE
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34782429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a T-cell receptor mimic antibody targeting a novel Wilms tumor 1-derived peptide and analysis of its specificity.
    Kurosawa N; Midorikawa A; Ida K; Fudaba YW; Isobe M
    Cancer Sci; 2020 Oct; 111(10):3516-3526. PubMed ID: 32770595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
    Brischwein K; Parr L; Pflanz S; Volkland J; Lumsden J; Klinger M; Locher M; Hammond SA; Kiener P; Kufer P; Schlereth B; Baeuerle PA
    J Immunother; 2007; 30(8):798-807. PubMed ID: 18049331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses.
    Sartorius R; Pisu P; D'Apice L; Pizzella L; Romano C; Cortese G; Giorgini A; Santoni A; Velotti F; De Berardinis P
    J Immunol; 2008 Mar; 180(6):3719-28. PubMed ID: 18322177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting of intracellular oncoproteins with peptide-centric CARs.
    Yarmarkovich M; Marshall QF; Warrington JM; Premaratne R; Farrel A; Groff D; Li W; di Marco M; Runbeck E; Truong H; Toor JS; Tripathi S; Nguyen S; Shen H; Noel T; Church NL; Weiner A; Kendsersky N; Martinez D; Weisberg R; Christie M; Eisenlohr L; Bosse KR; Dimitrov DS; Stevanovic S; Sgourakis NG; Kiefel BR; Maris JM
    Nature; 2023 Nov; 623(7988):820-827. PubMed ID: 37938771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.
    Ahmed M; Lopez-Albaitero A; Pankov D; Santich BH; Liu H; Yan S; Xiang J; Wang P; Hasan AN; Selvakumar A; O'Reilly RJ; Liu C; Cheung NV
    JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity.
    Ye S; Cohen D; Belmar NA; Choi D; Tan SS; Sho M; Akamatsu Y; Kim H; Iyer R; Cabel J; Lake M; Song D; Harlan J; Zhang C; Fang Y; Wahl AF; Culp P; Hollenbaugh D; Chao DT
    Cancer Immunol Res; 2019 Nov; 7(11):1864-1875. PubMed ID: 31462409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
    Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
    J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.
    Mandic M; Castelli F; Janjic B; Almunia C; Andrade P; Gillet D; Brusic V; Kirkwood JM; Maillere B; Zarour HM
    J Immunol; 2005 Feb; 174(3):1751-9. PubMed ID: 15661941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Augmentation of immune response by an analog of the antigenic peptide in a human T-cell clone recognizing mutated Ras-derived peptides.
    Yokomizo H; Matsushita S; Fujisao S; Murakami S; Fujita H; Shirouzu M; Yokoyama S; Ogawa M; Nishimura Y
    Hum Immunol; 1997 Jan; 52(1):22-32. PubMed ID: 9021406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes.
    Tahara K; Takesako K; Sette A; Celis E; Kitano S; Akiyoshi T
    Clin Cancer Res; 1999 Aug; 5(8):2236-41. PubMed ID: 10473111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin.
    Müller D; Karle A; Meissburger B; Höfig I; Stork R; Kontermann RE
    J Biol Chem; 2007 Apr; 282(17):12650-60. PubMed ID: 17347147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncogenic mutations in ras create HLA-A2.1 binding peptides but affect their extracellular antigen processing.
    Smith MC; Pendleton CD; Maher VE; Kelley MJ; Carbone DP; Berzofsky JA
    Int Immunol; 1997 Aug; 9(8):1085-93. PubMed ID: 9263005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Construction of optimized bispecific antibodies for selective activation of the death receptor CD95.
    Herrmann T; Grosse-Hovest L; Otz T; Krammer PH; Rammensee HG; Jung G
    Cancer Res; 2008 Feb; 68(4):1221-7. PubMed ID: 18281499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retargeting of adenoviral infection to melanoma: combining genetic ablation of native tropism with a recombinant bispecific single-chain diabody (scDb) adapter that binds to fiber knob and HMWMAA.
    Nettelbeck DM; Rivera AA; Kupsch J; Dieckmann D; Douglas JT; Kontermann RE; Alemany R; Curiel DT
    Int J Cancer; 2004 Jan; 108(1):136-45. PubMed ID: 14618628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma.
    Murata K; Nakatsugawa M; Rahman MA; Nguyen LT; Millar DG; Mulder DT; Sugata K; Saijo H; Matsunaga Y; Kagoya Y; Guo T; Anczurowski M; Wang CH; Burt BD; Ly D; Saso K; Easson A; Goldstein DP; Reedijk M; Ghazarian D; Pugh TJ; Butler MO; Mak TW; Ohashi PS; Hirano N
    Elife; 2020 Apr; 9():. PubMed ID: 32314731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An HLA-DRB1-derived peptide associated with protection against rheumatoid arthritis is naturally processed by human APCs.
    Snijders A; Elferink DG; Geluk A; van Der Zanden AL; Vos K; Schreuder GM; Breedveld FC; de Vries RR; Zanelli EH
    J Immunol; 2001 Apr; 166(8):4987-93. PubMed ID: 11290778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.